Overview

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Status:
Recruiting

Trial end date:
2027-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor. PRRT treatment is based on the administration of a radioactive product, 177-Lu DOTA-0-Tyr3-Octreotate (Lutathera®) and its use before and after surgery is thought to increase the overall survival benefit for patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors GEP-NETs.

Phase:

Phase 1

Details

Lead Sponsor:

Stanford University

Collaborators:

Advanced Accelerator Applications
Novartis Pharmaceuticals

Treatments:

Lutetium Lu 177 dotatate